Propanc Biopharma raises $108K in two convertible note financings in Feb 2025

Propanc Biopharma, Inc.

$65,000 convertible note (purchase price $56,000) issued Feb 6; 15% flat interest, maturity Nov 30, 2025.
$43,000 convertible note (purchase price $40,000) issued Feb 10; 8% annual interest, maturity Oct 7, 2025.
First note convertible at 35% discount to lowest 10-day trading price; second note at $9/share (or $6 if stock <$8 for 5 days).
Proceeds used for general working capital; notes sold in unregistered offerings under Rule 506(b) and Section 4(a)(2).
Both notes contain events of default including failure to pay, breach of covenants, and conversion share issuance delays.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.